Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion InfusionsDHA:ORIONINFU +0.10%81 PB Ratio is 17.96 as of Jul. 15, 2026, which is 199% above its 10-year median of 6.01. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 81/100 and a GF Value™ of BDT316.17 (Fairly Valued). The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, Orion Infusions ranks worse than 96.1% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-15), Orion Infusions's share price is BDT291.20. Orion Infusions's Book Value per Share for the quarter that ended in Mar. 2026 was BDT16.21. Hence, Orion Infusions's PB Ratio of today is 17.96.
Good Sign:
Orion Infusions Ltd stock PB Ratio (=18.36) is close to 3-year low of 17.31.
The historical rank and industry rank for Orion Infusions's PB Ratio or its related term are showing as below:
DHA:ORIONINFU'
s PB Ratio Range Over the Past 10 Years
Min: 3.49 Med: 6.01 Max: 65.79
Current: 17.97
During the past 13 years, Orion Infusions's highest PB Ratio was 65.79. The lowest was 3.49. And the median was 6.01.
DHA:ORIONINFU's PB Ratio is ranked worse than 96.1% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.92
vs DHA:ORIONINFU: 17.97
During the past 12 months, Orion Infusions's average Book Value Per Share Growth Rate was 3.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 3.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Orion Infusions was 22.80% per year. The lowest was -4.40% per year. And the median was 4.10% per year.
Back to Basics: PB Ratio
Orion Infusions (DHA:ORIONINFU) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Orion Infusions PB Ratio Related Terms
Orion Infusions PB Ratio Historical Data
* Premium members only.
The historical data trend for Orion Infusions's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONINFU vs ZTS, UTHR, VTRS: PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Infusions PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's PB Ratio distribution charts can be found below:
* The bar in red indicates where Orion Infusions's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Orion Infusions's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Orion Infusions (DHA:ORIONINFU) has a PB Ratio of 17.96 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Orion Infusions and its competitors. This is 199% above median its historical median of 6.01. Over the past decade, Orion Infusions' PB Ratio has ranged from 3.49 to 65.79. According to the industry distribution chart, Orion Infusions ranks #886 out of 922 companies in the Drug Manufacturers industry, placing it in the top 96.1%.
Is Orion Infusions' PB Ratio too high?
Orion Infusions' current PB Ratio of 17.96 is 199% above median its 10-year median of 6.01. Over the past 10 years, this metric has ranged from a low of 3.49 to a high of 65.79. The Drug Manufacturers industry median PB Ratio is 1.92. Orion Infusions' value of 17.96 is 835.4% above this industry median. Based on the distribution chart, Orion Infusions ranks #886 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orion Infusions has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orion Infusions ranks #886 out of 922 companies for PB Ratio. This places Orion Infusions in the lower half of its industry. The industry median PB Ratio is 1.92. Orion Infusions' value of 17.96 is 835.4% above this benchmark. Historically, Orion Infusions' own PB Ratio has ranged from 3.49 to 65.79 over the past decade. While the company's 10-year median is 6.01 vs. the industry median of 1.92, Orion Infusions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.92, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Infusions's current PB Ratio of 17.96 is 835.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Orion Infusions and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Infusions's current PB Ratio is 17.96, which is 199% above median its own 10-year median of 6.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Fairly Valued. The stock's GF Value™ is BDT316.17, compared to a current price of BDT291.20 — trading 7.9% below its estimated fair value. The current PB Ratio is 17.96, which is 199% above median its 10-year median of 6.01 and 835.4% above the Drug Manufacturers industry median of 1.92. Orion Infusions' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current PB Ratio is 17.96 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued.
The current stock price of BDT291.20 is trading 7.9% below its estimated GF Value™ of BDT316.17.
GuruFocus considers Orion Infusions to be Fairly Valued.
Key valuation signals for DHA:ORIONINFU:
PB Ratio: 17.96 (199% above median its 10-year median of 6.01)
GF Value™: BDT316.17 vs. price of BDT291.20 (7.9% below fair value)
Industry Position: 835.4% above the Drug Manufacturers median (#886 of 922)
No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
81GF Score
Get the complete analysis for DHA:ORIONINFU
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONINFU has been successfully added to your 
